PROGRAMMA SCIENTIFICO
Venerdì 05 Luglio 2024
12:00 – 13:30
Welcome lunch
Registration of Participants
13:30– 13:45
Introduction to kick-off meeting:
F. Di Raimondo (Catania) – A. Vacca (Bari)
SESSION 1
Demystifying the cell of origin of multiple myeloma
MODERATORS: G. Martinelli (Meldola) – T. Storlazzi (Bari)
14:00
The biology of plasma cell
S. Cenci (Milano)
14:15
How to investigate the cell of origin in multiple myeloma?
N. Bolli (Milano)
14:30
Splicing dysregulation drives myeloma aggressiveness
M.Cea (Genova)
14:45
How lcRNAs affect myeloma development?
E.Morelli (Candiolo)
15:00
Discussion
SESSION II
Smoldering Myeloma
MODERATORS: N. Giuliani (Parma) – M. Montagnani (Bari) –
15:15
Debate: Should we treat smoldering myeloma in 2025?
Yes: C. Cerchione (Meldola)
No: D. Derudas (Cagliari)
15:45
Transient regulatory T cell targeting triggers immune control of multiple myeloma and prevents disease progression
A.G. Beilhack (Würzburg)
16:00
How immunoparesis affects evolution in smoldering myeloma
F. Lazzaroni (Milano)
16:15
Televoter
A.Solimando (Bari)
16:30 – 17:00
Coffee Break
SESSION III
How immunotherapy can impact minimal residual disease
MODERATORS: V. Montefusco (Milano) – G.A. Palumbo (Catania)
17:00
How to study MRD in MM: the STREAMMING experience
M. Martello (Bologna)
17:15
Debate: Can MRD guide therapeutic options in myeloma?
Yes: F. Gay (Torino)
No: E. Zamagni (Bologna)
17:45
The CLL lesson: how MRD can guide targeted therapy?
M.Rossi (Cosenza)
18:15
T- cell dysfunction is relevant for MM relapse
M.Massaia (Cuneo)
18:30
How to trigger immune cell death in MM?
A. Gulla (Candiolo)
18:50
Televoter: N.L Parrinello (Catania)
19:00
Closing of the first day
Sabato 06 Luglio 2024
SESSION I
How to delay relapse at first line of treatment?
MODERATORS: M. Gentile (Cosenza) – N.Neri (Reggio Emilia)
08:30
Debate: Should we continue to transplant myeloma?
Yes: to warrant deeper responses
T. Petrucci (Roma)
No: to avoid the increase of mutation burden
M. Da Vià (Milano)
09:00
Should we continue to look for high-risk cytogenetics at relapse?
M. D’Agostino (Torino)
09:15
How to implement a biology-based patients’ classification model to describe the different MM clinical behaviors
C. Terragna (Bologna)
09:30
Televoter: C. Conticello (Catania)
SESSION II
Immunotherapy for relapse treatment
MODERATORS: U. Consoli (Catania)- C. Conticello (Catania)
09:45
Debate: How to sequence immunotherapies?
CAR-T first
R.Mina (Torino)
T-cell engagers firs
R. Zambello (Padova)
10:15
How to monitor T-cell fitness in myeloma
C. Botta (Palermo)
10:30
Televoter
A. Romano (Catania)
10:45 – 11:15
Coffee Break
SESSION III
Determinants of drug resistance: which treatment at later relapses?
MODERATORS:A. Corso (Pavia)- P. Musto (Roionero in Vulture)
11:15
How to trigger mitochondrial vulnerability?
N. Amodio (Catanzaro)
11:30
Cellular circuitries in the extra medullary disease
V. Desantis (Bari)
11:45
Metabolic features of myeloma cells in the context of bone microenvironment
P. Storti (Parma)
12:00
CRBN genomics drives sensitivity to immunomodulators
E. Borsi (Bologna)
12:15
Debate Should immunomodulators still be part of backbone of salvage regimens?
Yes: how pomalidomide, iberdomide and mezigdomide work
R. Ria (Bari)
No:what ixazomib or selinexor can add at first relapse
A.Furlan (Udine)
12:45
Emerging targets: inhibition of XPO-1and bcl-2 ,in myeloma
A. Solimando (Bari)
13:00
Televoter
F. Accardi (Palermo)
13:30- 14:30
Light Lunch
WORKSHOP: Spatial visualization of bone marrow niche
MODERATORS: A. Balduini (Firenze) – D. Tibullo (Catania)
14:30
The endothelial niche supports MM growth
A. Roccaro (Brescia)
14:45
Why spatial transcriptomics to understand microenvironment cancer?
L. Raimondi (Palermo)
15:00
A 3D model approach
M.Marchesini (Meldola)
15:15
High resolution live cells and fixed cells-based confocal microscopy
F. Pisani (Bari)
15:30
Myeloma evolution: a systems-thinking approach
F. Gonella (Padova) – A Romano (Catania)
15:45
LECTURE Deciphering the human plasma cell niche and its transformation in multiple myeloma
M.V. Dhodapkar (Atlanta)
17:00
Remarks and greetings
V. Desantis, F. Di Raimondo A. Solimando, A. Vacca
Test ECM
11
